The invention relates to dimensionally stable molded bone replacement elements made of mineral bone cement with residual hydraulic activity that contain at least one share of hardened mineral bone cement and at least one share of unconverted or unhardened reactive mineral bone cement, wherein the share of hardened mineral bone cement is 5% to 90% by weight. The dimensionally stable molded bone replacement elements have at least 5% of the maximum value of the strength of a completely hardened bone cement comprised of the same mineral components and with the same structural characteristics and reach compressive strengths in the range of 2 to 200 MPa. They are substantially free of water and can be converted under biological conditions.

The invention relates to dimensionally stable molded bone replacement elements made of mineral bone cement with residual hydraulic activity that contain at least one share of hardened mineral bone cement and at least one share of unconverted or unhardened reactive mineral bone cement, wherein the share of hardened mineral bone cement is 5% to 90% by weight. The dimensionally stable molded bone replacement elements have at least 5% of the maximum value of the strength of a completely hardened bone cement comprised of the same mineral components and with the same structural characteristics and reach compressive strengths in the range of 2 to 200 MPa. They are substantially free of water and can be converted under biological conditions.

A biocompatible controlled release form of complexed iodine is achieved by a complexation of polyvinyl alcohol based foam and characterized by a residual starch component to optimize iodine release profiles. The resulting iodine complexed polyvinyl alcohol foam may be utilized locally as an antimicrobial agent that releases controlled amounts of iodine sufficient to kill microbes for extended durations without excessive bulk and rigidity.

A biocompatible controlled release form of complexed iodine is achieved by a complexation of polyvinyl alcohol based foam and characterized by a residual starch component to optimize iodine release profiles. The resulting iodine complexed polyvinyl alcohol foam may be utilized locally as an antimicrobial agent that releases controlled amounts of iodine sufficient to kill microbes for extended durations without excessive bulk and rigidity.

Injectable, ready-to-use two-paste cement-forming compositions comprise a first paste and a second paste. The first paste comprises a non-aqueous oil-based suspension of monocalcium phosphate monohydrate (MCPM) powder, at least one surfactant effective to improve compatibility of the oil and the MCPM, and an organic acid, with an oil to MCMP powder weight ratio of about 0.2 to about 0.5. The second paste comprises an aqueous suspension of β-tricalcium phosphate (β-TCP) powder and a gel-forming polymer, with a water to β-TCP powder weight ratio of about 0.3 to about 0.5. The molar ratio of β-TCP powder to MCPM powder is greater than 1. An article of manufacture comprises a first compartment in which the first paste is contained, and a second compartment in which the second paste is contained. The compositions are useful for bone repair or replacement.

Injectable, ready-to-use two-paste cement-forming compositions comprise a first paste and a second paste. The first paste comprises a non-aqueous oil-based suspension of monocalcium phosphate monohydrate (MCPM) powder, at least one surfactant effective to improve compatibility of the oil and the MCPM, and an organic acid, with an oil to MCMP powder weight ratio of about 0.2 to about 0.5. The second paste comprises an aqueous suspension of β-tricalcium phosphate (β-TCP) powder and a gel-forming polymer, with a water to β-TCP powder weight ratio of about 0.3 to about 0.5. The molar ratio of β-TCP powder to MCPM powder is greater than 1. An article of manufacture comprises a first compartment in which the first paste is contained, and a second compartment in which the second paste is contained. The compositions are useful for bone repair or replacement.

To provide a liquid medical material maintaining a colloid in a more sol form than a solid at normal temperature, having a higher function as a wound dressing material and a hemostatic material than fibrin glue, and being able to be produced safely and inexpensively. A gelatin aqueous solution including calcium at a concentration of 0.2 M or more and 1.0 M or less, and having a concentration of 5% by weight or more and 40% by weight or less, an average molecular weight of 80,000 or more and 120,000 or less, and a molecular weight distribution of 20,000 or more and 300,000 or less, and transglutaminase inducing crosslinking of the gelatin, are included. It is preferable that the calcium has a concentration of 0.2 M or more and 0.7 M or less, the gelatin has a bloom of 160 or more and 250 or less, and the transglutaminase has activity per unit of 36 U/ml to 400 U/ml.

A sealant for sealing a puncture through tissue includes a first section, e.g., formed from freeze-dried hydrogel, and a second section extending from the distal end. The second section may be formed from PEG-precursors including PEG-ester and PEG-amine, e.g., in an equivalent ratio of active group sites of PEG-ester/PEG-amine greater than one-to-one, e.g., such that excess esters may provide faster activation upon contact with physiological fluids and enhance adhesion of the sealant within a puncture. At least some of the precursors remain in an unreactive state until exposed to an aqueous physiological environment, e.g., within a puncture, whereupon the precursors undergo in-situ cross-linking to provide adhesion to tissue adjacent the puncture. For example, the PEG-amine precursors may include the free amine form and the salt form. The free amine form at least partially cross-links with the PEG-ester and the salt form remains in the unreactive state in the sealant before introduction into the puncture.

A sealant for sealing a puncture through tissue includes a first section, e.g., formed from freeze-dried hydrogel, and a second section extending from the distal end. The second section may be formed from PEG-precursors including PEG-ester and PEG-amine, e.g., in an equivalent ratio of active group sites of PEG-ester/PEG-amine greater than one-to-one, e.g., such that excess esters may provide faster activation upon contact with physiological fluids and enhance adhesion of the sealant within a puncture. At least some of the precursors remain in an unreactive state until exposed to an aqueous physiological environment, e.g., within a puncture, whereupon the precursors undergo in-situ cross-linking to provide adhesion to tissue adjacent the puncture. For example, the PEG-amine precursors may include the free amine form and the salt form. The free amine form at least partially cross-links with the PEG-ester and the salt form remains in the unreactive state in the sealant before introduction into the puncture.

A sealant for sealing a puncture through tissue includes a first section, e.g., formed from freeze-dried hydrogel, and a second section extending from the distal end. The second section may be formed from PEG-precursors including PEG-ester and PEG-amine, e.g., in an equivalent ratio of active group sites of PEG-ester/PEG-amine greater than one-to-one, e.g., such that excess esters may provide faster activation upon contact with physiological fluids and enhance adhesion of the sealant within a puncture. At least some of the precursors remain in an unreactive state until exposed to an aqueous physiological environment, e.g., within a puncture, whereupon the precursors undergo in-situ cross-linking to provide adhesion to tissue adjacent the puncture. For example, the PEG-amine precursors may include the free amine form and the salt form. The free amine form at least partially cross-links with the PEG-ester and the salt form remains in the unreactive state in the sealant before introduction into the puncture.